Enalapril indications and usage: Difference between revisions
Amr Marawan (talk | contribs) (Created page with "__NOTOC__ {{Enalapril}} {{CMG}}; {{AE}} {{AM}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VASOTEC (ENALAPRIL MALEATE) TABLET VASOTEC (ENAL...") |
Amr Marawan (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AM}} | {{CMG}}; {{AE}} {{AM}} | ||
==INDICATIONS AND USAGE== | |||
====Hypertension==== | |||
VASOTEC is indicated for the treatment of [[hypertension]]. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VASOTEC (ENALAPRIL MALEATE) TABLET VASOTEC (ENALAPRIL MALEATE) TABLET [BTA PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d181743-a0fc-4d17-953d-b17a936f9ecc | publisher = | date = | accessdate = }}</ref> | VASOTEC is effective alone or in combination with other [[antihypertensive agents]], especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and [[thiazides]] are approximately additive. | ||
====Heart Failure==== | |||
VASOTEC is indicated for the treatment of symptomatic [[congestive heart failure]], usually in combination with diuretics and digitalis. In these patients VASOTEC improves symptoms, increases survival, and decreases the frequency of hospitalization. | |||
====Asymptomatic Left Ventricular Dysfunction==== | |||
In clinically stable asymptomatic patients with [[left ventricular dysfunction]] ([[ejection fraction]] ≤35 percent), VASOTEC decreases the rate of development of overt [[heart failure]] and decreases the incidence of hospitalization for heart failure. | |||
In using VASOTEC consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused [[agranulocytosis]], particularly in patients with [[renal impairment]] or [[collagen vascular disease]], and that available data are insufficient to show that VASOTEC does not have a similar risk. | |||
In considering use of VASOTEC, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving [[ACE inhibitors]] have been reported to have a higher incidence of angioedema compared to non-blacks.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VASOTEC (ENALAPRIL MALEATE) TABLET VASOTEC (ENALAPRIL MALEATE) TABLET [BTA PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d181743-a0fc-4d17-953d-b17a936f9ecc | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 19:36, 12 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
Enalapril
Enalapril and Hydrochlorothiazide
Enalapril and Felodipine
Overview
Enalapril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.
Category
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [4]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [5]
INDICATIONS AND USAGE
Hypertension
VASOTEC is indicated for the treatment of hypertension.
VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and thiazides are approximately additive.
Heart Failure
VASOTEC is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients VASOTEC improves symptoms, increases survival, and decreases the frequency of hospitalization.
Asymptomatic Left Ventricular Dysfunction
In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), VASOTEC decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. In using VASOTEC consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that VASOTEC does not have a similar risk.
In considering use of VASOTEC, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks.[1]
References
Adapted from the FDA Package Insert.